SOPHiA Artificial Intelligence Empowers Liquid Biopsies to Fight Cancer
Product News Jun 09, 2017
Sophia Genetics unveiled at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO) a new AI-powered solution for liquid biopsies. This new application taps the analytical power of the company’s artificial intelligence, SOPHiA, to help clinicians diagnose, treat, and monitor cancer earlier and more effectively by looking at circulating tumor DNA (ctDNA), or circulating tumor cells (CTC), contained in patients’ liquid samples such as blood, urine, and cerebral spinal fluid.
Compared to tissue biopsies, liquid biopsies allow clinicians to perform analysis of solid tumors and hematological malignancies at various time points to detect tumor progression and monitor treatments’ effectiveness. This new approach also represents a faster and less invasive alternative for patients.
The lack of a standardized analytical solution able to take into account different samples’ stability and low ctDNA levels has for a long time been a significant barrier to the widespread adoption of liquid biopsies in hospitals. SOPHiA solves these challenges by offering a standardized DNA analysis approach to liquid biopsy testing, built upon the network of 300 hospitals from 50 countries already using SOPHiA for genomic data analysis. Even with low ctDNA levels, SOPHiA provides indispensable insights into tumors’ profiles, straight from liquid samples.
One of the first users of SOPHiA for liquid biopsies, Prof. Léa Payen-Gay, co-investigator of the CIRCAN (“CIRculating CANcer”) program at the Hospices Civils de Lyon Laboratory, based in Lyon, France, explained, “SOPHiA helps save precious time and resources and serves as an excellent benchmark for our laboratory as it detects and validates a more comprehensive list of variants. The company’s analytical platform, SOPHiA DDM, is user-friendly and easy to navigate, making it possible for a user to be hands-on from benchtop to variant calling.”
Rather than waiting for months to detect changes on an imaging scan, SOPHiA allows clinicians to monitor a tumor’s progression with remarkable precision from a simple blood test. Faster and more accurate analysis eliminates undue anxiety resulting from biased answers and unclear response to heavy treatments, making regular status-check less stressful and painful for patients. SOPHiA’s application for liquid biopsies is also available for clinical trials, making it possible to identify the patients most likely to benefit from new treatments.
To facilitate the interpretation of all the genetic variants detected by SOPHiA in ctDNA, the analysis results are presented in the company’s OncoPortal, an interface dedicated to solid tumors and hematological malignancies, which experts can access on the company’s online analytical platform, Sophia DDM. OncoPortal flags associations between human gene variants, disease causality, progression, drug efficacy, and toxicity to help the clinicians better leverage the data analyzed by SOPHiA in order to provide personalized care to patients.
Jurgi Camblong, CEO and co-founder of Sophia Genetics, commented, “By applying SOPHiA’s state-of-the-art analytical power to liquid biopsies, clinicians can now leverage the collective intelligence of over 300 hospitals to help better diagnose, treat, and monitor cancer in a less invasive manner for patients. Now supporting tumor testing directly from blood samples with ctDNA, SOPHiA has the potential to benefit thousands of patients’ lives by giving clinicians access to the most advanced technology for cancer diagnosis and identification of successful treatments.”